Call Start: 16:30 January 1, 0000 5:20 PM ET

Revance Therapeutics, Inc. (NASDAQ:RVNC)

Q2 2022 Earnings Conference Call

August 9, 2022 16:30 ET

Company Participants

Jessica Serra - Head of Investor Relations & ESG

Mark Foley - Chief Executive Officer

Dustin Sjuts - President

Tobin Schilke - Chief Financial Officer & Principal Accounting Officer

Conference Call Participants

Seamus Fernandez - Guggenheim Partners

Ken Cacciatore - Cowen

Annabel Samimy - Stifel

David Amsellem - Piper Sandler

Tim Lugo - William Blair

Douglas Tsao - H.C. Wainwright

Serge Belanger - Needham & Company

Operator

Welcome to the Revance Therapeutics Second Quarter 2022 Financial Results and Corporate Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, Tuesday, August 9, 2022.

I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations and ESG for Revance. Please go ahead.

Jessica Serra

Thank you, Bella. Joining us on the call today from Revance, are Chief Executive Officer, Mark Foley; President, Dustin Sjuts; and Chief Financial Officer, Toby Schilke.

During this conference call, management will make forward-looking statements, including statements related to the regulatory process and potential approval for DaxibotulinumtoxinA for Injection [ph] in glabellar lines and in therapeutic indication, potential indications for RHA Redensity to the fact of RHA questions and open platform, consumer preferences, the benefits to us, practices and patients of our products and services, our financial performance, 2022 guidance, expected cash runway, strategic priorities and capital allocation plans, our market and revenue opportunity, our potential growth and our business strategy, planned operations and commercialization plans. Our actual results and the timeliness could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. Factors that could cause results to be different from these statements include factors the company describes in the section titled Risk Factors in our quarterly report on Form 10-Q filed with the SEC today, August 9, 2022. Revance undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events or changes in its expectations.

With that, I will turn the call over to Mark Foley, Chief Executive Officer of Revance. Mark?

Mark Foley

Thank you, Jessica. Good afternoon, everyone and thank you for joining our second quarter 2022 financial results conference call. We’re very pleased with our performance in the second quarter, highlighted by our best RHA quarter-to-date and solid account growth across our fillers and OPUL relational commerce platform. These results reflect the continued success of our launch and also the strength and resilience of the facial injectables market.